Kanakinumab w leczeniu pacjentów hospitalizowanych z powodu ciężkiego COVID-19
Termedia,
Źródło: JAMA Network Redaktor: Bogusz Soiński |Data: 14.10.2021 Wyniki randomizowanego badania klinicznego dotyczącego…
Źródło: JAMA Network Redaktor: Bogusz Soiński |Data: 14.10.2021 Wyniki randomizowanego badania klinicznego dotyczącego…
Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center.
medwireNews: Treatment with the interleukin (IL)-1β inhibitor canakinumab does not improve the likelihood of survival without…
1. Among patients hospitalized with severe COVID-19 and hyperinflammation, treatment using the anti-interleukin-1β antibody…
July 20, 2021 2 min read Source/Disclosures Published by: Disclosures: The researchers report funding Novartis.
Data show no significant difference in survival rates in the canukinumab group (88.8%) compared to placebo (85.7%).
An arthritis drug does not significantly increase a severe COVID-19 patient's chance of survival, a new study finds.
An arthritis drug does not significantly increase a severe COVID-19 patient’s chance of survival, a new study finds.
An arthritis drug does not significantly increase a severe COVID-19 patient’s chance of survival, a new study finds.